Brief: Medincell Says Uzedy Net Sales Increased 63% To $191 Million In 2025
Jan 28 (Reuters) - Medincell SA MEDCL.PA: UZEDY NET SALES INCREASED 63% TO $191 MILLION IN 2025 SUBMISSION OF OLANZAPINE LAI IN EUROPEAN UNION FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS IS EXPECTED IN Q2 2026 RECEIVES MID‑TO HIGH‑SINGLE-DIGIT ROYALTIES ON UZEDY NET SALES AND IS ELIGIBLE FOR UP TO $105 MILLION IN COMMERCIAL MILESTONE PAYMENTS TEVA PROJECTS 2026 NET SALES OF $250-$280 MILLION Source text: ID:nBw6Vsplba Further company coverage: MEDCL.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Medincell SA
See all newsBrief: Medincell Has Secured An Additional EUR 13.8 Million In Non-Dilutive Financing From Leading European Commercial Banks And Bpifrance
Teva gains after FDA approves monthly schizophrenia injection
Corrected: UPDATE 1-Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva wins FDA approval for monthly schizophrenia injection Weltruza
Brief: Medincell Announces Temporary Shares Trading Suspension On Euronext Paris